Patents Assigned to Cytochroma Inc.
-
Patent number: 8906888Abstract: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: April 25, 2006Date of Patent: December 9, 2014Assignees: Cytochroma Inc., Johns Hopkins UniversityInventors: Uttam Saha, Gary H. Posner, Mehmet Kahraman
-
Publication number: 20140113886Abstract: A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.Type: ApplicationFiled: January 2, 2014Publication date: April 24, 2014Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Patent number: 8592401Abstract: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.Type: GrantFiled: April 25, 2008Date of Patent: November 26, 2013Assignees: Proventiv Therapeutics, LLC, Cytochroma Inc.Inventors: P. Martin Petkovich, Charles W. Bishop, Eric J. Messner, Keith H. Crawford
-
Publication number: 20130178451Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: ApplicationFiled: November 19, 2012Publication date: July 11, 2013Applicants: PROVENTIV THERAPEUTICS, LLC, CYTOCHROMA INC.Inventors: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLC
-
Publication number: 20130157987Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: January 13, 2011Publication date: June 20, 2013Applicants: JOHNS HOPKINS UNIVERSITY, CYTOCHROMA INC.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Publication number: 20130131022Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: January 22, 2013Publication date: May 23, 2013Applicants: PROVENTIV THERAPEUTICS, LLC, CYTOCHROMA INC.Inventors: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLC
-
Patent number: 8361488Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: April 25, 2008Date of Patent: January 29, 2013Assignees: Cytochroma Inc., Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Samir P. Tabash, Sammy Asiamah Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
-
Patent number: 8329677Abstract: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: June 21, 2007Date of Patent: December 11, 2012Assignees: Cytochroma, Inc., Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, Martin P. Petkovich, Christian F. Helvig
-
Patent number: 8207149Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: September 26, 2011Date of Patent: June 26, 2012Assignees: Cytochroma, Inc., Proventiv Therapeutics, LLCInventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, Sammy A. Agudoawu, Eric J. Messner, P. Martin Petkovich
-
Publication number: 20120130133Abstract: Processes for preparing vitamin D2 derivatives and intermediates to vitamin D2 derivatives are disclosed. An improved photolysis process for the preparation of cis intermediate (I) from the trans starting material (II) are disclosed. Also disclosed is an improved process for the formation of a trans double bond at C22-C23 of the vitamin D2 derivative, which provides high selectivity of the desired trans double bond of compound (III) over the undesired cis double bond of compound (IIIA).Type: ApplicationFiled: November 25, 2009Publication date: May 24, 2012Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Publication number: 20120094396Abstract: Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.Type: ApplicationFiled: May 3, 2010Publication date: April 19, 2012Applicant: CYTOCHROMA INC.Inventors: P. Martin Petkovich, Christian F. Helvig
-
Publication number: 20120028926Abstract: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.Type: ApplicationFiled: January 26, 2010Publication date: February 2, 2012Applicant: CYTOCHROMA INC.Inventors: Uttam Saha, Christian F. Helvig, P. Martin Petkovich
-
Patent number: 8106035Abstract: The present invention provides novel D-ring and side-chain analogs of 1?,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: December 18, 2003Date of Patent: January 31, 2012Assignee: Cytochroma Inc.Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Hong Woon Yang, Steven M. Silverman, Byung-Chul Suh, Jay A. White, Glenville Jones, Uttam Saha, Heung Bae Jeon
-
Patent number: 8039676Abstract: A process for producing a compound of the formula: including reacting of a compound of the formula: with diphenyl phosphine oxide using a binary phase reaction mixture including diphenyl phosphine oxide in an organic solvent, a basic aqueous solution, and a phase transfer catalyst, to obtain the compound of formula 1, wherein Ph is phenyl, X1 and X2 are both hydrogen or X1 and X2 taken together are CH2, R1 is a protecting group, R2 is fluorine, hydrogen, or OR3, wherein R3 is a protecting group, and the squiggly line represents a bond that results in the adjacent double bond being in either the E or Z configuration, is disclosed.Type: GrantFiled: May 29, 2008Date of Patent: October 18, 2011Assignee: Cytochroma Inc.Inventor: Uttam Saha
-
Publication number: 20100120728Abstract: The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.Type: ApplicationFiled: April 25, 2008Publication date: May 13, 2010Applicant: CYTOCHROMA INC.Inventors: P. Martin Petkovich, Christian F. Helvig, Samir P. Tabash
-
Publication number: 20100008902Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.Type: ApplicationFiled: August 24, 2009Publication date: January 14, 2010Applicant: CYTOCHROMA INC.Inventors: Jay A. White, Martin P. Petkovich, Glenville Jones, Heather Ramshaw
-
Patent number: 7579329Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. It is also expressed in normal and tumour lung tissue and in breast cancer cells and may have a correlation with lung and breast cancer. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders, cancer and certain brain disorders.Type: GrantFiled: August 3, 2006Date of Patent: August 25, 2009Assignee: Cytochroma Inc.Inventors: Jay A. White, Martin P. Petkovich, Glenville Jones, Heather Ramshaw
-
Publication number: 20090176748Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: April 25, 2008Publication date: July 9, 2009Applicants: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLCInventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, Sammy Asiamah Agudoawu
-
Patent number: 7537919Abstract: The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders and cancer.Type: GrantFiled: December 15, 2000Date of Patent: May 26, 2009Assignee: Cytochroma Inc.Inventors: Jay White, Martin P Petkovich, Glenville Jones, Heather Ramshaw
-
Publication number: 20090082317Abstract: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: ApplicationFiled: April 25, 2006Publication date: March 26, 2009Applicants: CYTOCHROMA INC., JOHNS HOPKINS UNIVERSITYInventors: Uttam Saha, Gary H. Posner, Mehmet Kahraman